Barrett's oesophagus: Epidemiology, cancer risk and implications for management

Gut

Volumn 63, Issue 1, 2014, Pages 191-202

  De Jonge, Pieter Jan F ^a   Van Blankenstein, Mark ^a   Grady, William M ^b,c   Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AGE; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAPSULE ENDOSCOPY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SURVEILLANCE; DYSPLASIA; ENDOSCOPIC BIOPSY; ENVIRONMENTAL FACTOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRODUODENOSCOPY; ETHNIC DIFFERENCE; GASTROESOPHAGEAL REFLUX; HUMAN; LOW GRADE DYSPLASIA; PREVALENCE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ADENOCARCINOMA; BARRETT'S OESOPHAGUS; EPIDEMIOLOGY; SURVEILLANCE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 84889668102     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305490     Document Type: Article

References (187)

1. Morson BC, Belcher Jr. Adenocarcinoma of the oesophagus and ectopic gastric mucosa. Br J Cancer 1952;6:127-30.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7.
4. Dikken JL, Lemmens VE, Wouters MW, et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 2012;48:1624-32.
5. el-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002;31:421-40, viii. (Pubitemid 34761220)
6. de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-6.
7. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986;315:362-71. (Pubitemid 16060091)
8. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97. (Pubitemid 351406009)
9. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011;140:e18-52; quiz e13.
10. Boyer J, Laugier R, Chemali M, et al. French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett's esophagus. Endoscopy 2007;39:840-2. (Pubitemid 47386837)
11. Committee ASoP, Evans JA, Early DS, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012;76:1087-94.
12. Harnish DC. Estrogen receptor ligands in the control of pathogenic inflammation. Curr Opin Investig Drugs 2006;7:997-1001. (Pubitemid 44756126)
13. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology Guidelines. Diagnosis and Management of Barrett's oesophagus. Submitted 2013.
14. Corley DA, Mehtani K, Quesenberry C, et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013;145:312-19 e1.
15. Armstrong D. Should patients with Barrett's oesophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol 2008;22:721-39. (Pubitemid 352034206)
16. Barritt ASt, Shaheen NJ. Should patients with Barrett's oesophagus be kept under surveillance? The case against. Best Pract Res Clin Gastroenterol 2008;22:741-50. (Pubitemid 352016335)
17. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33. (Pubitemid 34049191)
18. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7. (Pubitemid 37500431)
19. Ward EM, Wolfsen HC, Achem SR, et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006;101:12-7. (Pubitemid 43381703)
20. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31. (Pubitemid 41772961)
21. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57:1354-9.
22. Zou D, He J, Ma X, et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol 2011;46:133-41.
23. van Blankenstein M, Looman CW, Johnston BJ, et al. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005;100:568-76. (Pubitemid 40487554)
24. van Soest EM, Siersema PD, Dieleman JP, et al. Age and sex distribution of the incidence of Barrett's esophagus found in a dutch primary care population. Am J Gastroenterol 2005;100:2599-600.
25. Coleman HG, Bhat S, Murray LJ, et al. Increasing incidence of Barrett's oesophagus: a population-based study. Eur J Epidemiol 2011;26:739-45.
26. Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009;58:16-23.
27. den Hoed C, van Blankenstein M, Dees J, et al. The interval between the diagnosis of long segment Barrett's esophagus and symptomatic esophageal adenocarcinoma as found in an observational cohort followed up for 35 years. Gastroenterology 2010;138:S-169-70.
28. Nilsson M, Lundegardh G, Carling L, et al. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scand J Gastroenterol 2002;37:626-30 (Pubitemid 34620921)
29. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53. (Pubitemid 28525384)
30. Ford AC, Forman D, Reynolds PD, et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005;162:454-60. (Pubitemid 41191431)
31. Bersentes K, Fass R, Padda S, et al. Prevalence of Barrett's esophagus in Hispanics is similar to Caucasians. Dig Dis Sci 1998;43:1038-41. (Pubitemid 28211464)
32. Abrams JA, Fields S, Lightdale CJ, et al. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008;6:30-4. (Pubitemid 50008419)
33. Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009;58:182-8.
34. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9. (Pubitemid 32269555)
35. Irani S, Parkman HP, Thomas R, et al. Increased Barrett's esophagus for the decade between 1991 and 2000 at a single university medical center. Dig Dis Sci 2005;50:2141-6. (Pubitemid 41504103)
36. Prach AT, MacDonald TA, Hopwood DA, et al. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997;350:933. (Pubitemid 27420536)
37. Coleman HG, Bhat S, Murray LJ, et al. Increasing incidence of Barrett's oesophagus: a population-based study. Eur J Epidemiol 2011;26:739-45.
38. van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005;54:1062-6. (Pubitemid 41025895)
39. El-Serag HB, Mason AC, Petersen N, et al. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368-72. (Pubitemid 34161053)
40. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23:3155-62.
41. Dikken JL, Lemmens VE, Wouters MW, et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 2012;48:1624-32.
42. Rokkas T, Pistiolas D, Sechopoulos P, et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007;5:1413-7, 17 e1-2.
43. Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 2008;57:727-33. (Pubitemid 351716961)
44. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;19:145.
45. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
46. Sykora J, Malan A, Zahlava J, et al. Gastric emptying of solids in children with H. pylori-positive and H. pylori-negative non-ulcer dyspepsia. J Pediatr Gastroenterol Nutr 2004;39:246-52.
47. den Hoed CM, Vila AJ, Holster IL, et al. Helicobacter Pylori and the Birth Cohort Effect: evidence for stabilized colonization rates in childhood. Helicobacter 2011;16:405-09.
48. Kuipers EJ, Pena AS, van Kamp G, et al. Seroconversion for Helicobacter pylori. Lancet 1993;342:328-31. (Pubitemid 23227561)
49. Haruma K. Review article: influence of Helicobacter pylori on gastro-oesophageal reflux disease in Japan. Aliment Pharmacol Ther 2004;20(Suppl 8):40-4. (Pubitemid 39657666)
50. McColl KE. Review article: helicobacter pylori and gastro-oesophageal reflux disease-the European perspective. Aliment Pharmacol Ther 2004;20(Suppl 8):36-9. (Pubitemid 39657665)
51. Yagi K, Nakamura A, Sekine A, et al. Endoscopic findings of adenocarcinoma arising from short-segment Barrett's esophagus. J Gastroenterol Hepatol 2004;19:940-3. (Pubitemid 39093218)
52. Bahmanyar S, Zendehdel K, Nyren O, et al. Risk of oesophageal cancer by histology among patients hospitalised for gastroduodenal ulcers. Gut 2007;56:464-8. (Pubitemid 46580499)
53. Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets. Cancer Epidemiol 2011;35:309-19.
54. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008;57:281-4. (Pubitemid 351288088)
55. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006;130:639-49. (Pubitemid 43374513)
56. Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007;132:883-9. (Pubitemid 46440865)
57. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut 2007;56:749-55. (Pubitemid 46854185)
58. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34-41; quiz 311. (Pubitemid 47031134)
59. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133:403-11. (Pubitemid 47187351)
60. El-Serag HB, Kvapil P, Hacken-Bitar J, et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005;100:2151-6.
61. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008;247:909-15. (Pubitemid 351770409)
62. Beasley LE, Koster A, Newman AB, et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring) 2009;17:1062-9.
63. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006;147:4505-16. (Pubitemid 44268402)
64. Corley DA, Kubo A, Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 2007;56:756-62. (Pubitemid 46854187)
65. Hill JO, Sidney S, Lewis CE, et al. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr 1999;69:381-7. (Pubitemid 29104556)
66. Stanforth PR, Jackson AS, Green JS, et al. Generalized abdominal visceral fat prediction models for black and white adults aged 17-65 y: the HERITAGE Family Study. Int J Obes Relat Metab Disord 2004;28:925-32. (Pubitemid 39005694)
67. Kanaley JA, Giannopoulou I, Tillapaugh-Fay G, et al. Racial differences in subcutaneous and visceral fat distribution in postmenopausal black and white women. Metabolism 2003;52:186-91. (Pubitemid 36388841)
68. Demerath EW, Rogers NL, Reed D, et al. Significant associations of age, menopausal status and lifestyle factors with visceral adiposity in African-American and European-American women. Ann Hum Biol 2011;38:247-56.
69. Park YW, Allison DB, Heymsfield SB, et al. Larger amounts of visceral adipose tissue in Asian Americans. Obes Res 2001;9:381-7. (Pubitemid 33603863)
70. Heard-Costa NL, Zillikens MC, Monda KL, et al. NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet 2009;5:e1000539.
71. Lindgren CM, Heid IM, Randall JC, et al. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet 2009;5:e1000508.
72. Schokker DF, Visscher TL, Nooyens AC, et al. Prevalence of overweight and obesity in the Netherlands. Obes Rev 2007;8:101-8.
73. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. Jama 2006;295:1549-55.
74. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8. (Pubitemid 30621983)
75. Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg 2007;246:11-21. (Pubitemid 47012200)
76. Thomas T, Abrams KR, De Caestecker JS, et al. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007;26:1465-77. (Pubitemid 350178802)
77. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-49. (Pubitemid 352019777)
78. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44; quiz e32.
79. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009;104:502-13.
80. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-6.
81. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000;321:1252-5.
82. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of Adenocarcinoma among Patients with Barrett's Esophagus. N Engl J Med 2011;365:1375-83.
83. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.
84. van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8. (Pubitemid 26239094)
85. Solaymani-Dodoran M, Logan RFA, West J, et al. Mortality associated with Barrett' esophagus and gastroesophageal reflux disease diagnoses- a population based cohort study. Am J Gastroenterol 2005;100:2616-21.
86. Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2007.
87. Cook MB, Wild CP, Everett SM, et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007;16:2090-6. (Pubitemid 47621185)
88. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001;111:33-7. (Pubitemid 32635259)
89. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4. (Pubitemid 36877416)
90. Schouten LJ, Steevens J, Huysentruyt CJ, et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011;9:754-61.
91. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
92. Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005;162:1050-61. (Pubitemid 41746617)
93. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol 2001;33:306-9. (Pubitemid 32880970)
94. Johansson J, Hakansson HO, Mellblom L, et al. Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007;42:148-56.
95. Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007;13:1585-94. (Pubitemid 46672669)
96. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
97. Smith KJ, O'Brien SM, Green AC, et al. Current and past smoking significantly increase risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:840-8.
98. Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and esophageal adenocarcinoma consortium. Gastroenterology 2012;142:744-53.
99. Thrift AP, Pandeya N, Smith KJ, et al. Lifetime alcohol consumption and risk of Barrett's Esophagus. Am J Gastroenterol 2011;106:1220-30.
100. Steevens J, Schouten LJ, Driessen AL, et al. A prospective cohort study on overweight, smoking, alcohol consumption, and risk of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2011;20:345-58.
101. Kubo A, Levin TR, Block G, et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009;136:806-15.
102. Anderson LA, Cantwell MM, Watson RG, et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009;136:799-805.
103. Crabb DW, Berk MA, Hall TR, et al. Familial gastroesophageal reflux and development of Barrett's esophagus. Ann Intern Med 1985;103:52-4. (Pubitemid 15068499)
104. Jochem VJ, Fuerst PA, Fromkes JJ. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology 1992;102:1400-2.
105. Fahmy N, King JF. Barrett's esophagus: an acquired condition with genetic predisposition. Am J Gastroenterol 1993;88:1262-5. (Pubitemid 23219724)
106. Chak A, Ochs-Balcom H, Falk G, et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006;15:1668-73. (Pubitemid 44497103)
107. Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002;51:323-8.
108. Sun X, Elston R, Barnholtz-Sloan J, et al. A segregation analysis of Barrett's esophagus and associated adenocarcinomas. Cancer Epidemiol Biomarkers Prev 2010;19:666-74.
109. Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011;306:410-9.
110. Su Z, Gay LJ, Strange A, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012;44:1131-6.
111. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31. (Pubitemid 29142625)
112. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-7. (Pubitemid 40559260)
113. Shaheen NJ, Dulai GS, Ascher B, et al. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol 2005;100:577-80. (Pubitemid 40487555)
114. Arguedas MR, Eloubeidi MA. Barrett's oesophagus: a review of costs of the illness. Pharmacoeconomics 2001;19:1003-11. (Pubitemid 33701930)
115. The role of endoscopy in the management of GERD: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1999;49:834-5.
116. Eisen GM, Baron TH, Dominitz JA, et al. Complications of upper GI endoscopy. Gastrointest Endosc 2002;55:784-93.
117. Kruijshaar ME, Kerkhof M, Siersema PD, et al. The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Endoscopy 2006;38:873-8. (Pubitemid 44430683)
118. Shaheen NJ, Green B, Medapalli RK, et al. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology 2005;129:429-36. (Pubitemid 41096631)
119. Chang JY, Talley NJ, Locke GR III, et al. Population screening for barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc 2011;86:1174-80.
120. Zaman A, Hapke R, Sahagun G, et al. Unsedated peroral endoscopy with a video ultrathin endoscope: patient acceptance, tolerance, and diagnostic accuracy. Am J Gastroenterol 1998;93:1260-3. (Pubitemid 29076924)
121. Atkinson M, Das A, Faulx A, et al. Ultrathin esophagoscopy in screening for Barrett's esophagus at a Veterans Administration Hospital: easy access does not lead to referrals. Am J Gastroenterol 2008;103:92-7.
122. Eliakim R, Sharma VK, Yassin K, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 2005;39:572-8. (Pubitemid 41061261)
123. Eliakim R, Yassin K, Shlomi I, et al. A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule. Aliment Pharmacol Ther 2004;20:1083-9. (Pubitemid 39657941)
124. Bhardwaj A, Hollenbeak CS, Pooran N, et al. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009;104:1533-39.
125. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010;341:c4372.
126. Lao-Sirieix P, Boussioutas A, Kadri SR, et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009;58:1451-59.
127. Benaglia T, Sharples LD, Fitzgerald RC, et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013;144:62-73 e6.
128. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40. (Pubitemid 34173814)
129. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. does it help? J Thorac Cardiovasc Surg 1993;105:383-7; discussion 87-8.
130. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol 2002;97:1319-27. (Pubitemid 34664771)
131. Van der Veen AH, Dees J, Blankensteijn JD, et al. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-8. (Pubitemid 19038565)
132. Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006;10:1-142, iii-iv.
133. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86. (Pubitemid 36231623)
134. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53. (Pubitemid 29374530)
135. McArdle JE, Lewin KJ, Randall G, et al. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-82.
136. Nasr JY, Schoen RE. Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia. J Gastrointest Oncol 2011;2:34-8.
137. Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007;102:1154-61. (Pubitemid 46802035)
138. Fitzgerald RC, Saeed IT, Khoo D, et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001;46:1892-8. (Pubitemid 32844155)
139. Curvers WL, Peters FP, Elzer B, et al. Quality of Barrett's surveillance in The Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol 2008;20:601-7.
140. Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009;7:736-42; quiz 10.
141. Curvers WL, van Vilsteren FG, Baak LC, et al. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc 2011;73:195-203.
142. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial. Gut 2012;62:15-21.
143. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002;51:671-6. (Pubitemid 35216854)
144. Sharma P. Low-grade dysplasia in Barrett's esophagus. Gastroenterology 2004;127:1233-8. (Pubitemid 39345891)
145. Kerkhof M, van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007;50:920-7. (Pubitemid 46850080)
146. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523-30.
147. Prasad GA, Bansal A, Sharma P, et al. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010;105:1490-502.
148. Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show same male predominance - due to 17 year delayed development in females. Gut 2008;58:16-23.
149. Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003;48:1537-41. (Pubitemid 36936690)
150. Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005;242:49-54. (Pubitemid 40917967)
151. Sikkema M, Looman CW, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol 2011;106:1231-8.
152. Guardino JM, Khandwala F, Lopez R, et al. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol 2006;101:2187-93. (Pubitemid 44477541)
153. Bani-Hani KE, Bani-Hani BK, Martin IG. Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. World J Gastroenterol 2005;11:6807-14. (Pubitemid 43092452)
154. den Hoed CM, van Blankenstein M, Dees J, et al. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. Br J Cancer 2011;105:200-205.
155. de Jonge PJ, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2006;101:1421-9. (Pubitemid 43980612)
156. Moe GL, Kristal AR, Levine DS, et al. Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000;36:7-13. (Pubitemid 30317829)
157. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52. (Pubitemid 34851909)
158. Menke-Pluymers MB, Hop WC, Dees J, et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993;72:1155-8. (Pubitemid 23224979)
159. Gray MR, Donnelly RJ, Kingsnorth AN. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. Gut 1993;34:727-31. (Pubitemid 23185093)
160. Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-6.
161. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999;94:3413-9.
162. Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol
163. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42. (Pubitemid 29374529)
164. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
165. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85. (Pubitemid 29055349)
166. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20. (Pubitemid 30217553)
167. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39:1175-9. (Pubitemid 39656830)
168. Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220-7; quiz e26.
169. Wong T, Tian J, Nagar AB. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010;123:462-7.
170. Tharavej C, Hagen JA, Peters JH, et al. Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc 2006;20:439-43. (Pubitemid 43260503)
171. Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 2008;67:604-9.
172. Pech O, Gossner L, Manner H, et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007;39:588-93. (Pubitemid 47098994)
173. Moons LM, Kusters JG, Bultman E, et al. Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol 2005;207:269-76. (Pubitemid 41556450)
174. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9. (Pubitemid 32523482)
175. Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007;102:483-93; quiz 694. (Pubitemid 46328161)
176. Timmer MR, Sun G, Gorospe EC, et al. Predictive biomarkers for Barrett's esophagus: so near and yet so far. Dis Esophagus 2013;26:574-81.
177. Varghese S, Lao-Sirieix P, Fitzgerald RC. Identification and clinical implementation of biomarkers for Barrett's esophagus. Gastroenterology 2012;142:435-41 e2.
178. Younes M, Ertan A, Lechago LV, et al. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701. (Pubitemid 27196015)
179. Skacel M, Petras RE, Rybicki LA, et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol 2002;97:2508-13.
180. Kaye PV, Haider SA, Ilyas M, et al. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009;54:699-712.
181. Sikkema M, Kerkhof M, Steyerberg EW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol 2009;104:2673-80.
182. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2012;Dec 20. Epub ahead of print.
183. Hirst NG, Gordon LG, Whiteman DC, et al. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol 2011;26:247-54.
184. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336-46.
185. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009;136:2101-14 e1-6.
186. Hur C, Choi SE, Rubenstein JH, et al. The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. Gastroenterology 2012;143:567-75.
187. Titi M, Overhiser A, Ulusarac O, et al. Development of Sub-Squamous High-Grade Dysplasia and Adenocarcinoma after Successful Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology 2012;143:564-6.